About Us

Our Mission at Bonne Santé Group

We aim to create a world-class nutraceutical company engaged in the development, manufacturing and sales of quality nutraceutical and related health and lifestyle products for distribution to an expanding global marketplace. Bonne Santé Group has launched a major broad-based initiative designed to capture significant market share in this quickly expanding industry on a highly accelerated basis.

Expert Management

Even before our IPO, Bonne Santé has attracted an outstanding leadership team whose members bring decades of practical experience and success in all of the disciplines necessary to launch what we believe will be an inter-national powerhouse.

Opportunity For Growth

The nutraceutical marketplace is projected to surpass $568 billion by 2023. This rapid growth is being driven by consumers in markets across the world taking more responsibility for their wellbeing and educating themselves about healthy living.

No Stone Unturned

With a dedicated state-of-the-art manufacturing facility coupled to a world-class team with skills that range from the science of nutraceuticals with in-house chemists and formulators, to finance and capital markets, manufacturing and sales, data management and direct marketing, Bonne Santé is well positioned for major success.

Real Results

The Next Few Years

The management team and the board of directors of Bonne Santé intend to create a major international nutraceutical company with a stated objective of reaching a minimum of $250 million in revenues within the first three years through the manufacturing and marketing a wide range of world-class nutraceutical products and next-generation delivery technologies.

Nutraceutical Industry bn 2017

Nutraceutical Industry bn 2022E


Private-to-Public Company Pathway to Initial Public Offering

In addition to quality and good health, Bonne Santé is committed to early and significant value for our investors. Senior management of BSG, along with our team of associated professionals, has substantial capital markets expertise. The Company is filing an Initial Public Offering upon completion of its next phase of acquisitions. As a public company, BSG has the ability to create a larger audience of potential investors.


Bonne Santé employs analysts who are tasked with identifying companies that are profitable and lend themselves to BSG’s consolidation strategies. Management seeks to find profitable companies where acquisitions can be made with private valuations, but where public company valuations for companies in the sector may have valuations in an appropriate range.

We’d love to hear from you!

Please feel free to ask us any questions you may have. You can reach us using any of the methods below:




(786) 749-1221


990 Biscayne Blvd., Suite 1203,
Miami, Florida 33132